Type 2 diabetes. Type 2 diabetes
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive 1 capsules of 250 milligrams of ellagic acid (product by Exir Gostar Espadana Co. and made in The Iran) for 8 weeks a day. Inte
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Willingness to cooperate Diabetes type 2 Age 60-30 years Patients whose blood sugar is well controlled by taking oral hypoglycemic drugs. Body Mass Index (BMI): 23-35 kg / m2 Both sexes
Exclusion criteria
Exclusion criteria: Reluctance to cooperate Taking multivitamin and mineral supplements during the last 3 months Follow a specific diet and physical activity for the past 3 months Taking corticosteroids and nonsteroidal anti-inflammatory drugs Insulin users Chronic diseases such as cardiovascular, renal, hepatic and hypothyroidism and hyperthyroidism. Having specific physiological conditions such as pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of fasting blood sugar (FBS). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of fasting blood sugar (FBS) by enzymatic method.;Level of insulin. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of insulin by enzymatic method.;Level of hemoglobin A1C. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of hemoglobin A1C by enzymatic method.;HOMA-IR scores. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of HOMA-IR score using formula.;Serum level of total cholesterol (TC). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of total cholesterol (TC) level via enzymatic kit.;Serum level of triglyceride. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of triglyceride (TG) level via enzymatic kit.;Serum level of HDL. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of HDL level via enzymatic kit.;Serum level of LDL. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of LDL using friedewald equation.;Serum level of total antioxidant capacity (TAC). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of total antioxidant capacity (TAC) by spectrophotometry.;Assessment of the body composition. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Assess body composition using the body composition analyzer.;Serum level of malondialdehyde (MDA). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of malondialdehyde (MDA) by spectrophotometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Physical activity level. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Via IPAQ questionnaire.;Assessment of dietary intake. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: 3-day food record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Taghdir
Bagheiat-allah University of Medical Sciences
Outcome results
None listed